Results 221 to 230 of about 1,104,984 (330)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Simulation-Based Spatially Explicit Close-Kin Mark-Recapture. [PDF]

Mol Ecol Resour
Patterson G, Goodfellow CK, Ting N, Kern AD, Ralph PL.   +4 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Trends in Adoption of Familial Hypercholesterolemia Diagnostic Code E78.01 Across U.S. Health Care Databases, 2016-2024. [PDF]

JACC Adv
Osei J, Najarro G, Sperling L, Khoury MJ, Sun YV.   +4 more
europepmc   +1 more source

The analysis and the trend of ethical researches on genetic doping

, 2012
Mizuho TAKEMURA
openalex   +2 more sources

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Trends in Childhood and Adolescent Cancer Incidence Rates in the United States between 2001 and 2022. [PDF]

Cancer Discov
Shiels MS, Haque AT, Jones RR, Kitahara CM, Glod JW, Widemann BC, Morton LM, Chanock SJ, Savage SA.   +8 more
europepmc   +1 more source

Modelling Lactation Curves and Estimating Genetic Parameters Across Lactation Stages of Pure Fogera Cattle: Integrating Climate-Induced Genetic Trends

Demelash Kassahun Adimas, Mekonnen Tilahun, Mulugeta Meseret, Eyasu Lakew, Mesfin Lakew, Assemu Tesfa, Addisu Bitew, Tewodros Bimrow, Bekahegn Wondim, Mehari Ayalew, Adebabay Kebede, Adebabay Adane, Demelash Dagnaw, Getinet Mekuriaw   +13 more
openalex   +1 more source

Core Negotiation Issues for Digital Sequence Information on Genetic Resources under CBD and its Protocols and their Trend

, 2020
Won Seog Park
openalex   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source